1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort
(
- Contribution to journal › Article
- 2011
-
Mark
Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study
(
- Contribution to journal › Article
- 2010
-
Mark
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
(
- Contribution to journal › Article
-
Mark
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.
(
- Contribution to journal › Article
- 2009
-
Mark
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
(
- Contribution to journal › Article
-
Mark
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2007
-
Mark
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
(
- Contribution to journal › Article
-
Mark
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
(
- Contribution to journal › Article